Hitachi air conditioning units kill viruses and bacteria
Also deliver the most comfortable level of heating and cooling
The S Series units kill airborne viruses, bacteria and odour by generating ionised mist from the air in the room.
Each unit automatically cleans its micro-mesh stainless filter once the air conditioning operation has ended; removing dust from the filter and collecting it in a dust box. Its internal cleaning operation also controls mould growth.
Hitachi says the units are energy-efficient, having a Coefficient of Performance (COP) of 6.13 and EER of 6.0, and cost around £18 a year to run.
The units also offer cutting-edge temperature control, which monitors and controls all aspects of the air humidity and air quality. Its DC inverter technology allows a room to reach the required temperature rapidly ensuring maximum user comfort. The inverter technology then adjusts the speed of the system’s ‘Eco-Scroll’ compressor to an energy saving mode, in order to maintain the desired temperature as efficiently as possible.
A ‘Real Dry’ function sets humidity levels within the room at 40–70% (in 5% increments). It also enables noise levels of 20dB(A).
Glyn Jones, UK product marketing manager at Hitachi, said: “The S-Series is air conditioning at its very best – from its compact stylish design to its abilities to save energy, money and eliminate bacteria.”
You may also like
Trending Articles
Upcoming event
You may also like
Design & Build
Scitech-EKIUM wins Cleanroom Technology Best Cleanroom Design Award
While the project faced significant delivery challenges, most notably construction on the 15th floor of a live hospital, the strength of the design itself lay in its adaptability, technical coordination, and strong alignment with user needs
Containment
FDA warning letter flags serious violations at New Jersey manufacturing facility for GLP-1 weight loss jabs
The US Food and Drug Administration has issued a warning letter of deficient cleanroom design, contamination controls and quality oversight in sterile GLP-1 drug production at a New Life Pharma facility
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.